ES2238268T3 - Medicamento para el tratamiento de la hipertension sanguinea. - Google Patents

Medicamento para el tratamiento de la hipertension sanguinea.

Info

Publication number
ES2238268T3
ES2238268T3 ES00903681T ES00903681T ES2238268T3 ES 2238268 T3 ES2238268 T3 ES 2238268T3 ES 00903681 T ES00903681 T ES 00903681T ES 00903681 T ES00903681 T ES 00903681T ES 2238268 T3 ES2238268 T3 ES 2238268T3
Authority
ES
Spain
Prior art keywords
group
alkyl
phenyl
forms
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00903681T
Other languages
English (en)
Spanish (es)
Inventor
Martin R. Wilkins
Dirk Thormahlen
Harald Waldeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2238268T3 publication Critical patent/ES2238268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES00903681T 1999-02-16 2000-02-10 Medicamento para el tratamiento de la hipertension sanguinea. Expired - Lifetime ES2238268T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19906310 1999-02-16
DE19906310A DE19906310A1 (de) 1999-02-16 1999-02-16 Arzneimittel zur Behandlung von Bluthochdruck

Publications (1)

Publication Number Publication Date
ES2238268T3 true ES2238268T3 (es) 2005-09-01

Family

ID=7897580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00903681T Expired - Lifetime ES2238268T3 (es) 1999-02-16 2000-02-10 Medicamento para el tratamiento de la hipertension sanguinea.

Country Status (28)

Country Link
US (1) US6482820B2 (US06262066-20010717-C00315.png)
EP (1) EP1154777B1 (US06262066-20010717-C00315.png)
JP (1) JP2002537258A (US06262066-20010717-C00315.png)
KR (2) KR100797665B1 (US06262066-20010717-C00315.png)
CN (1) CN1198619C (US06262066-20010717-C00315.png)
AR (1) AR036864A1 (US06262066-20010717-C00315.png)
AT (1) ATE295174T1 (US06262066-20010717-C00315.png)
AU (1) AU773240C (US06262066-20010717-C00315.png)
BR (1) BR0008260A (US06262066-20010717-C00315.png)
CA (1) CA2362273C (US06262066-20010717-C00315.png)
CZ (1) CZ301499B6 (US06262066-20010717-C00315.png)
DE (2) DE19906310A1 (US06262066-20010717-C00315.png)
DZ (1) DZ3014A1 (US06262066-20010717-C00315.png)
ES (1) ES2238268T3 (US06262066-20010717-C00315.png)
HK (1) HK1042247B (US06262066-20010717-C00315.png)
HU (1) HUP0105491A3 (US06262066-20010717-C00315.png)
IL (1) IL144622A (US06262066-20010717-C00315.png)
NO (1) NO329588B1 (US06262066-20010717-C00315.png)
NZ (1) NZ514058A (US06262066-20010717-C00315.png)
PL (1) PL195283B1 (US06262066-20010717-C00315.png)
PT (1) PT1154777E (US06262066-20010717-C00315.png)
RU (1) RU2270679C2 (US06262066-20010717-C00315.png)
SK (1) SK287254B6 (US06262066-20010717-C00315.png)
TR (1) TR200102386T2 (US06262066-20010717-C00315.png)
TW (1) TWI221770B (US06262066-20010717-C00315.png)
UA (1) UA63032C2 (US06262066-20010717-C00315.png)
WO (1) WO2000048601A1 (US06262066-20010717-C00315.png)
ZA (1) ZA200105828B (US06262066-20010717-C00315.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
EP1234025B1 (en) * 1999-11-19 2008-08-27 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
CA2357833C (en) * 2000-10-04 2005-11-15 Warner-Lambert Company Treatment of pulmonary hypertension using vasopressin antagonist
RU2003136077A (ru) * 2001-05-18 2005-08-10 Зольвай Фармасьютиклз Гмбх (De) Применение соединений, обладающих совместной ингибирующей активностью в отношении nep (нейтральная эндопептидаза) и мр (металлопротеаза), для приготовления лекарственных средств
PT1448567E (pt) * 2001-09-10 2010-03-12 Tibotec Pharm Ltd Método de preparação de hexa-hidro-furo[2,3-b]furan-3-ol
RU2303041C2 (ru) 2002-01-16 2007-07-20 Солвей Фармасьютикалс Б.В. Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
TWI344366B (en) 2003-11-18 2011-07-01 Solvay Pharm Gmbh Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
MX2007006279A (es) 2004-12-15 2007-06-14 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
KR20100135729A (ko) * 2008-01-31 2010-12-27 반더빌트유니버시티 폐의 용태에 따른 치료 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel

Also Published As

Publication number Publication date
TR200102386T2 (tr) 2002-01-21
TWI221770B (en) 2004-10-11
NZ514058A (en) 2001-09-28
BR0008260A (pt) 2001-11-06
HK1042247A1 (en) 2002-08-09
WO2000048601A1 (de) 2000-08-24
DE19906310A1 (de) 2000-08-17
SK287254B6 (sk) 2010-04-07
CA2362273C (en) 2010-05-25
HK1042247B (zh) 2005-09-23
DZ3014A1 (fr) 2004-03-27
CZ301499B6 (cs) 2010-03-24
HUP0105491A2 (en) 2002-06-29
ZA200105828B (en) 2002-07-15
CZ20012672A3 (cs) 2002-02-13
EP1154777B1 (de) 2005-05-11
SK10822001A3 (sk) 2002-03-05
UA63032C2 (en) 2004-01-15
CN1339966A (zh) 2002-03-13
PL195283B1 (pl) 2007-08-31
KR100797665B1 (ko) 2008-01-23
RU2270679C2 (ru) 2006-02-27
JP2002537258A (ja) 2002-11-05
PL350167A1 (en) 2002-11-18
AU773240C (en) 2004-11-18
US6482820B2 (en) 2002-11-19
NO329588B1 (no) 2010-11-15
KR20070027719A (ko) 2007-03-09
US20020052361A1 (en) 2002-05-02
DE50010284D1 (de) 2005-06-16
PT1154777E (pt) 2005-07-29
AU2547600A (en) 2000-09-04
KR20010101922A (ko) 2001-11-15
NO20013958L (no) 2001-10-15
HUP0105491A3 (en) 2002-08-28
AR036864A1 (es) 2004-10-13
CN1198619C (zh) 2005-04-27
NO20013958D0 (no) 2001-08-15
CA2362273A1 (en) 2000-08-24
IL144622A (en) 2006-08-20
EP1154777A1 (de) 2001-11-21
AU773240B2 (en) 2004-05-20
ATE295174T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
ES2238268T3 (es) Medicamento para el tratamiento de la hipertension sanguinea.
ES2259289T3 (es) Formulacion de benzamida con actividad inhibidora de la histona desacetilasa.
EP0498069B1 (en) New use of peptide derivative
ES2339213T3 (es) Clorhidrato de lercanidipino amorfo
JP2002537258A5 (US06262066-20010717-C00315.png)
BR112013020424A2 (pt) Nitrocatecol substituído, utilizações do mesmo, combinação e composição que o compreendem
RU2268727C2 (ru) Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
US4416893A (en) Substituted 1,2,5-oxadiazole-2-oxides in human cardiovascular system disease
HU207220B (en) Process for producing pharmaceutical composition for diminishing enhanced pressure of the pulmonary circulation
PT93654A (pt) Processo para a preparacao de composicoes farmaceuticas sinergicas contendo 3-{2-{4-(4-fluoro-benzoil)-1-piperidinil}etil}-2,4-(1h,3h)-quinazolina-diona (ketanserina)
US3922340A (en) Pharmaceutical compositions for treating lung diseases
ES2199461T3 (es) Antagonista de endotelina y bloqueador de los beta receptores a modo de preparado en combinacion.
JP2002255814A (ja) アスピリンを含有する医薬組成物
ES2252751T3 (es) Medicamento para el corazon pulmonar.
WO1994005290A1 (en) Platelet aggregation inhibitor
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
ES2289305T3 (es) Medicamento para el tratamiento del "sindrome de la respuesta inflamatoria sistemica".
JPH02262519A (ja) 糖尿病性神経障害治療剤
US3777026A (en) N-substituted amino-n-nitroso-amino-acetonitriles as anti-anginal agents
US3821381A (en) Method of treatment
ES2210331T3 (es) Uso de 4-amino-6-hidroxipirazol (3,4-d) pirimidina en la preparacion de un agente antihipertensivo.
US3749781A (en) Pharmaceutical composition and method of treatment
JPS62286924A (ja) 抗高脂血症剤
ES2332565B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios.
JPWO2018012634A1 (ja) 不飽和複素5員環含有化合物を含有する肺高血圧症の予防又は治療剤